

Use of Target Values in EQA

Dr. Anja Kessler Bonn, Germany


External Quality Assessment

Example: Progesterone

580 participants

Measurement principles:


Luminescence detection Radioactivity detection Fluorescence detection Mass spectrometry



Which result is accurate? Are the results comparable within certain limits?

www.rfb.bio

. . .




Traceability for Measurands in EQA - present state-



Alpha-fetoprotein Carbamazepine C-reactive protein Ferritin IgA, IgG,IgM pCO₂, pO₂ Valproic acid





RiliBÄK – Table B1a

| 1 | 2 | 3 | 4 | | | 5 | 6 |
|-----|-----------------------------------|---|---|-------------|--------|---|--------------------------------|
| No. | Measurand | Permissible relative deviation of a single result or the relative root mean | Rili-BAEK a concentrat of columns | ion interva | | Permissible relative deviation in EQA | Type of target value in EQA |
| | | square, respectively | From | To Ur | nit | | |
| | | | | | | | |
| L | Carbamacepine | 12.09 | 6 2 | 20 | mg/L | 20. | .0% NV |
| 2 | Carcinoembryonic antigen (CEA) | 14.0% | 6 1 | 200 | μg/L | 24. | .0% NV |
| 3 | Chloride | 4.5% | 6 70 | 150 | mmol/l | . 8. | .0% RMV |
| 4 | Cholesterol (total) | 7.09 | 6 50 | 350 | mg/dL | 13. | .0% RMV |
| | | | 1.3 | 9.1 | mmol/l | L | |
| 5 | Cortisol | 16.09 | 6 >60 | 500 | μg/L | 30. | .0% RMV |
| | | | >166 | 1380 | nmol/L | | |
| | | 18.5% | 6 20 | ≤60 | μg/L | | |
| | | | 55 | ≤166 | nmol/L | | |
| 5 | Creatine kinase (CK) EC | 11.09 | 6 50 | 1000 | U/L | 20. | .0% RMV |
| | 2.7.3.2 | | 0.83 | 16.7 | µkat/L | | |
| 7 | C-reactive protein (CRP) | 13.59 | 61 | 120 | mg/L | 20. | .0% NV |
| 8 | Digitoxin | 15.5% | 65 | 80 | μg/L | 30. | .0% RMV |
| 9 | Digoxin | 14.09 | 6 >1 | 5 | μg/L | 30. | .0% RMV |
| | | 17.59 | 6 0.5 | ≤1 | μg/L | | |
| | Erythrocytes | 4.09 | 6 1.5 | 7 | 1012/L | 8. | .0% RMV |
| | Oestradiol 17-beta | 22.09 | 6 10 | 500 | ng/L | 35. | .0% RMV |
| | | | 37 | 1835 | pmol/L | | |

Referenzinstitut für Bioanalytik

Kit Dependent Target Values



B 50

40

30


20

10

ag/bl


26,4


25.779




Traceability for Measurands in EQA - present state-










RiliBÄK – Table B1a


| D. | 2 Measurand | Permissible relative deviation of a single result or the relative root mean | 4 Rili-BAEK a concentrat of columns | ion interva | als | 5 Permissible relative deviation in EQA | | e of target e in EQA |
|----|-----------------------------------|---|--|-------------|--------|--|-----|-------------------------|
| | | square, respectively | From | To U | nit | | | |
| | | | | | | | | |
| | Carbamacepine | 12.09 | 6 2 | 20 | mg/L | 20 | .0% | NV |
| | Carcinoembryonic antigen (CEA) | 14.09 | 6 1 | 200 | µg/L | 24 | .0% | NV |
| | Chloride | 4.59 | 6 70 | 150 | mmol/l | . 8 | .0% | RMV |
| | Cholesterol (total) | 7.09 | 6 50 | 350 | mg/dL | 13 | .0% | RMV |
| | | | 1.3 | 9.1 | mmol/l | | | |
| | Cortisol | 16.09 | 6 >60 | 500 | μg/L | 30 | .0% | RMV |
| | | | >166 | 1380 | nmol/L | | | |
| | | 18.5% | 6 20 | ≤60 | μg/L | | | |
| | | | 55 | ≤166 | nmol/L | | | |
| | Creatine kinase (CK) EC | 11.09 | | 1000 | U/L | 20 | .0% | RMV |
| | 2.7.3.2 | | 0.83 | 16.7 | µkat/L | | | |
| | C-reactive protein (CRP) | 13.59 | | 120 | mg/L | | .0% | NV |
| | Digitoxin | 15.5% | | 80 | μg/L | | .0% | RMV |
| | Digoxin | 14.09 | | 5 | μg/L | 30 | .0% | RMV |
| | | 17.59 | | ≤1 | μg/L | _ | | |
| | Erythrocytes | 4.0% | | 7 | 1012/L | | .0% | RMV |
| | Oestradiol 17-beta | 22.09 | | 500 | ng/L | | .0% | RMV |
| | | | 37 | 1835 | pmol/L | | | |


Referenzinstitut für Bioanalytik

Enzymes – Situation before Standardization



Enzymes – Situation after Standardization







www.rfb.bio

Referenzinstitut für Bioanalytik

Traceability for Measurands in EQA - present state-







RiliBÄK – Table B1a

| 1 No. | 2 Measurand | deviation of a single result | 4 Rili-BAEK applicable concentration intervals of columns 3 and 5 | | | 5 Permissible relative deviation in EQA | 6 Type of target value in EQA | |
|----------|-----------------------------------|------------------------------|--|-------------|----------------|--|-------------------------------------|-----|
| | | square, respectively | From | To Un | it | III EQA | | |
| | | | | | | | | |
| | Carbamacepine | 12.09 | 6 2 | 20 | mg/L | 20 | .0% | NV |
| | Carcinoembryonic antigen (CEA) | 14.09 | 6 1 | 200 | µg/L | 24 | .0% | NV |
| 3 | Chloride | 4.5% | 6 70 | 150 | mmol/L | . 8 | .0% | RMV |
| | Cholesterol (total) | 7.09 | | 350 | mg/dL | | .0% | RMV |
| | 6 . H. I | | 1.3 | 9.1 | mmol/L | | | |
| | Cortisol | 16.09 | | 500 | μg/L | | .0% | RMV |
| | | 18.5% | >166 % 20 | 1380 ≤60 | nmol/L | | | |
| | | 18.5 | ⁻⁰ 20 55 | ≤166 | µg/L nmol/L | | | |
| | Creatine kinase (CK) EC | 11.09 | | 1000 | U/L | | .0% | RMV |
| | 2.7.3.2 | 11.0 | 0.83 | 16.7 | µkat/L | 20 | .0 /0 | |
| | C-reactive protein (CRP) | 13.59 | | 120 | mg/L | 20 | .0% | NV |
| | Digitoxin | 15.59 | | 80 | μg/L | | .0% | RMV |
| | Digoxin | 14.09 | % >1 | 5 | μg/L | 30 | .0% | RMV |
| | | 17.59 | 6 0.5 | ≤1 | μg/L | | | |
| | Erythrocytes | 4.09 | 6 1.5 | 7 | 1012/L | 8 | .0% | RMV |
| | Oestradiol 17-beta | 22.09 | 6 10 | 500 | ng/L | 35 | .0% | RMV |
| | | | 37 | 1835 | pmol/L | | | |

RfB Referenzinstitut für Bioanalytik

Survey ,Hormones'




<u>HM1/16</u>

Estradiol-17beta

Lumineszenzmessung - Kit 44

Split 1




| number of results | 153 | | | | |
|--------------------------|--------------|---------------|--|--|--|
| target value | 1,04 | 0,276 | | | |
| limits | 0,676 - 1,41 | 0,179 - 0,373 | | | |
| mean | 1,015 | 0,24 | | | |
| standarddeviation | 0,08 | 0,026 | | | |
| coefficient of variation | 7,852 | 10,974 | | | |

<u>HM1/16</u>

Estradiol-17beta

Lumineszenzmessung - Kit 13

Split 1



| number of results | 35 | | | | | |
|--------------------------|--------------|---------------|--|--|--|--|
| target value | 1,04 | 0,276 | | | | |
| limits | 0,676 - 1,41 | 0,179 - 0,373 | | | | |
| mean | 1,163 | 0,304 | | | | |
| standarddeviation | 0,12 | 0,048 | | | | |
| coefficient of variation | 10,361 | 15,636 | | | | |

Joint Committee for Traceability in Laboratory Medicine









http://www.bipm.org : JCTLM database

REFERENCE MEASUREMENT SYSTEMS

- Reference materials
- Reference measurement procedures
- Services of reference measurement laboratories



Reference Measurement Systems




The laboratory has to make use of a reference measurement procedure approved according to ISO 15193 and reference materials approved according to ISO 15194.


The laboratory has to be accreditated according to ISO/IEC 17025 and ISO 15195.

The laboratory has to participate regularly in **collaborative surveys** for calibration laboratories.

EQA for Calibration Laboratories




EQA for Calibration Laboratories





EQA for Calibration Laboratories






Linking Routine and Calibration Laboratories

Testosterone

HM 1/16 vs. RELA2014



- 680 routine labs
- 3 calibration labs

Limits of Acceptance: 35%

www.rfb.bio

Referenzinstitut für Bioanalvtik

Implementation of Traceability



- The implementation of quality assurance for clinical measurands requires the support of
- National Metrology Institutes
- •Scientific Societies of Clinical Chemistry and Laboratory Medicine
- Accreditation Bodies
- Suppliers of Certified Reference Materials
- Calibration Laboratories
- (also known as: Reference Measurement Laboratories)
- •IVD Industry
- •External Quality Assessment Organizers
- •Legal Authorities
- Medical Laboratories themselves

Summary and Outlook



About 40 reference measurement systems are available to assign independent target values for interlaboratory comparisons. (most frequently analysed measurands)

However, many measurands still have to be evaluated by method/kit dependent target values.

Scientific work is necessary to develop reference measurement systems for further measurands in laboratory medicine.

The implementation of traceability in laboratory medicine and the improvement of comparability of EQA results depend on the contribution of many parties.